RxDoctor Payments DataLook up a doctor →

Marcello Rotta, MD

Hematology & Oncology · Denver, CONPI 1700107075

Payments from drug & device makers

$764,787in general payments, 2019–2025

Across 843 payments — averaging $907.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$291K
  • AbbVie$110K
  • Incyte Corporation$104K
  • Seagen Inc.$79K
  • Bristol Myers Squibb$49K
  • Pfizer$31K
  • plus $102K from 34 others
$330in research payments, 2019–2025

Across 1 payment — averaging $330.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$330

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$764,787 in reported general payments places this provider in the 75th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$1,045,179
Medicare patients
239
Services billed
38,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →